{
    "clinical_study": {
        "@rank": "117810", 
        "acronym": "STELLA_Ext", 
        "arm_group": {
            "arm_group_label": "Cilostazol", 
            "arm_group_type": "Other", 
            "description": "Cilostazol 50mg and 100mg"
        }, 
        "brief_summary": {
            "textblock": "This study will be conducted in accordance with the local regulation of New Drug\n      Application. Overall duration of this trial will be 3 years after approval of MFDS.\n\n      Each subject will participate around 26 weeks, which include the 24 weeks treatment period\n      and 2 weeks safety follow up period. Withdrawn subjects due to efficacy after 4 weeks\n      treatment will partcipate in 6 weeks in total including 2 weeks safety follow up. Withdrawn\n      subjects with other reason also have 2 weeks follow up period."
        }, 
        "brief_title": "Safety and Efficacy Study of Cilostazol to Treat Vasapastic Angina", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Vasospastic Angina", 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Angina Pectoris, Variant"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Multicenter, One group, Open-label Study. Cilostazol will be treated for additional 24\n      weeks to the subject who had completed 021-KOA-1301i study. Pletaal\u00d2(Cilostazol) is taken\n      100mg oral tablets bid during 2 3weeks after dosing of Pletaal\u00d2(Cilostazol) 50mg oral\n      tablets bid during 1 week. The dose can be adjusted by investigator's discretion during the\n      study and the detailed method is described in the Protocol. Subject who has 2 or more chest\n      pain at 4th week will be withdrawn from the study (But, subjects who show 50% or more of\n      chest pain decrease compared to 1st week would not be withdrawn.). Subjects who participated\n      in this trial will have 2 weeks follow-up after study completion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - 1. Male or female 20 or over the age of 20 and under the age of 80. But, patients who\n        were 80 years at the time of 021-KOA-1301i enrollment and who are now 81 years, are\n        eligible for this trial.\n\n        2. Subjects who completed 021-KOA-1301i study. 3. Women must be postmenopausal (for at\n        least 1 year), incapable of pregnancy, or, if sexually active and capable of pregnancy, be\n        practicing an acceptable method of birth control (e.g., hormonal contraceptives,\n        intrauterine device, male condom+spermicide, female condom+spermicide, male partner\n        sterilization) 4. Ability to provide own written informed consent after receiving a full\n        explanation for this study\n\n        Exclusion Criteria:\n\n          1. Subjects who have exclusion criteria at the enrollment of 021-KOA-1301i study.\n\n          2. Subjects who have exclusion criteria from 021-KOA-1301i enrollment to visit 1 of\n             021-KOA-1302i. The exclusion criteria is as below.\n\n               -  Myocardial infarction or Myocardial infarction by vasospastic angina at\n                  screening\n\n               -  Life threatening vasospastic events such as ventricular tachycardia ,\n                  ventricular fibrillation, or syncope\n\n               -  Stroke, intracranial hemorrhage, or TIA\n\n               -  Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper\n                  gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous\n                  hemorrhage, etc.)\n\n          3. Subjects who are now taking the prohibited medication of 021-KOA-1301i.\n             (Investigational Products of 021-KOA-1301i are permitted.)\n\n          4. Clinical laboratory test results of visit 1 are identified as following criteria at\n             visit 2.\n\n               -  Subjects with severe anemia of Hemoglobin \u2264 6.5 g/dl at screening\n\n               -  Creatinine \u2265 1.5 mg/dL at screening\n\n               -  Aspartate transaminase (AST) or alanine transaminase (ALT) > 3 times the upper\n                  limit of normal (ULN) at screening\n\n               -  Platelet < 100,000 mm3 at screening\n\n          5. Tachycardia; Heart rate > 100 bpm, at Screening via vital sign\n\n          6. Hypotension of diastolic pressure < 90 mmHg at screening\n\n          7. Uncontrolled hypertension, defined as \u2265 160 mmHg systolic or \u2265 100 mmHg diastolic at\n             Screening\n\n          8. QT prolongation defined as baseline QTcB > 450 msec for males or QTcB > 470 msec for\n             females at Screening.\n\n          9. Women of childbearing potential who have positive pregnancy test result at screening\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094469", 
            "org_study_id": "021-KOA-1302i"
        }, 
        "intervention": {
            "arm_group_label": "Cilostazol", 
            "description": "Oral, Bid, 24 weeks", 
            "intervention_name": "Cilostazol", 
            "intervention_type": "Drug", 
            "other_name": "Pletaal"
        }, 
        "intervention_browse": {
            "mesh_term": "Cilostazol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Treatment for vasospastic angina", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "junehongk@gmail.com", 
                "last_name": "Junghong Kim, MD", 
                "phone": "82-10-8231-7171"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "626-770"
                }, 
                "name": "Yangsan Busan University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)", 
        "overall_official": {
            "affiliation": "Yangsan Busan University Hospital", 
            "last_name": "Junghong Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of subjects without chest pain on the final a week/final 2 weeks after 24 weeks treatment.", 
            "measure": "Proportion of subjects without chest pain on the final a week/final 2 weeks after 24 weeks treatment.", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094469"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change/Percent change of the chest pain frequency on the final a week/final 2 weeks after 24 weeks treatment compared to final a week/final 2 weeks on Amlodipine run-in period of 021-KOA-1301i.", 
                "measure": "secondary 1", 
                "safety_issue": "No", 
                "time_frame": "24 week"
            }, 
            {
                "description": "Change of the chest pain intensity on the final a week/final 2 weeks after 24 weeks treatment compared to final a week/final 2 weeks on Amlodipine run-in period of 021-KOA-1301i.", 
                "measure": "secondary 2", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Cumulative proportion of withdrawn subjects due to lack of efficacy at every 4 weeks.", 
                "measure": "secondary 3", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}